Skip to main content
Clinical Trials/DRKS00003204
DRKS00003204
Recruiting
Not Applicable

on-interventional study for the analysis of efficacy and safety of EstraCept(R) 280 mg (Estramustin phosphate) at patients with castration resistant prostate cancer in three therapy situations - EMPire

PharmaCept GmbH0 sites300 target enrollmentAugust 3, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C61
Sponsor
PharmaCept GmbH
Enrollment
300
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 3, 2011
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Male

Investigators

Sponsor
PharmaCept GmbH

Eligibility Criteria

Inclusion Criteria

  • Castration resistant prostate cancer
  • Advanced status
  • Hormone refractory
  • Signed patient informed consent

Exclusion Criteria

  • As described in the product information

Outcomes

Primary Outcomes

Not specified

Similar Trials